Do ARBs Increase Cancer Risk?

Key Takeaways

• MR study links ACE‑I/ARB use to reduced risk of five major cancers
• Losartan does not directly cause muscle weakness in older heart‑failure patients
• Switching to an ACE inhibitor offers no proven strength benefit, but may cause cough
• Renal protection and blood‑pressure control remain primary reasons to keep ARBs

Pulse Analysis

The perception that angiotensin‑receptor blockers (ARBs) increase cancer risk has been challenged by a large‑scale Mendelian randomization analysis published on PubMed. By leveraging genetic variants that mimic drug exposure, researchers demonstrated a causal protective effect of both ACE inhibitors and ARBs against gastric, colorectal, lung, breast, and endometrial cancers. The protective signal appears partially mediated through lower vascular endothelial growth factor‑A (VEGF‑A) and improved lipid profiles, suggesting that these drugs may influence tumor biology beyond blood‑pressure control. For clinicians, the findings reinforce confidence in prescribing ARBs without fearing heightened oncologic risk, especially in populations already vulnerable to cancer.

In the context of geriatric heart‑failure management, losartan remains a favored ARB because it effectively lowers blood pressure, mitigates proteinuria, and avoids the dry cough that frequently limits ACE‑inhibitor use. Current evidence does not associate losartan with muscle weakness or functional decline; reported fatigue in elderly patients is more often linked to volume overload, beta‑blocker side effects, or deconditioning after acute events. Consequently, swapping losartan for an ACE inhibitor solely to boost strength lacks scientific support and could introduce cough, hyperkalemia, or renal function fluctuations.

Decision‑making for an 89‑year‑old patient should prioritize renal protection, hemodynamic stability, and overall tolerability. If the patient tolerates losartan well and shows no cough or angioedema, maintaining the ARB is reasonable. Should an ACE inhibitor be considered, clinicians must monitor for cough and renal changes, and weigh any marginal benefits against potential adverse effects. Ultimately, individualized therapy—guided by comorbidities, lab values, and patient preference—offers the best pathway to preserving independence and quality of life.